|Articles|June 1, 1997

June 1997
Volume 3
Issue 6

Cost of Illness Studies for Schizophrenia: Components, Benefits, Results, and Implications

Author(s)Laura A. Genduso, PharmD, Jane Castelli Haley, MBA

Download PDF: Cost of Illness Studies for Schizophrenia: Components, Benefits, Results, and Implications

Articles in this issue

about 29 years ago

Article

Issues of Medical Necessity: A Medical Director's Guide to Good Faith Adjudication

about 29 years ago

Article

Asthma Treatment Costs Using Inhaled Corticosteroids

about 29 years ago

Article

Costs, True Costs, and Whose Costs in Economic Analyses in Medicine?

about 29 years ago

Article

The Challenge of Integrating Monoclonal Antibodies into the Current Healthcare System

about 29 years ago

Article

Prostate Cancer Screening

about 29 years ago

Article

Breast Reconstruction After Mastectomy

about 29 years ago

Article

Exploring Self-Care and Wellness: A Model for Pharmacist Compensation by Managed Care Organizations

about 29 years ago

Article

Breast-Feeding and Managed Care

about 29 years ago

Article

Correspondence regarding, "The Political Economy of Capitated Managed Care"

about 29 years ago

Article

Economic Advantages of Breast-Feeding in an HMO Setting: A Pilot Study

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Cost of Illness Studies for Schizophrenia: Components, Benefits, Results, and Implications

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access